Evidence map›Paper›PMID 27033541›Full record

ArticleEndocrine2016

AIP mutations in young patients with acromegaly and the Tampico Giant: the Mexican experience.

Claudia Ramírez-Rentería, Laura C Hernández-Ramírez, Lesly Portocarrero-Ortiz, Guadalupe Vargas, Virgilio Melgar, Etual Espinosa, Ana Laura Espinosa-de-Los-Monteros, Ernesto Sosa, Baldomero González, Sergio Zúñiga and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Novel AIP mutation in exon 6 causing acromegaly in a German family.Journal of endocrinological investigation · 2023
    Article
  5. Review
  6. Growth Hormone and Aging: Updated Review.The world journal of men's health · 2019
    Review
  7. Article
  8. Endocrine connections · 2017
    Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 10 institutions in 3 countries.

Claudia Ramírez-RenteríaExperimental Endocrinology Unit/Endocrine Service, Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Sur 132 number 142, Suite 210, Colonia las Americas, Mexico City, 01120, Mexico.
Laura C Hernández-RamírezCentre for Endocrinology, The William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London, UK.
Lesly Portocarrero-OrtizEndocrinology Service, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico.
Guadalupe VargasExperimental Endocrinology Unit/Endocrine Service, Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Sur 132 number 142, Suite 210, Colonia las Americas, Mexico City, 01120, Mexico.
Virgilio MelgarNeurological Center, Centro Médico ABC, Mexico City, Mexico.
Etual EspinosaExperimental Endocrinology Unit/Endocrine Service, Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Sur 132 number 142, Suite 210, Colonia las Americas, Mexico City, 01120, Mexico.
Ana Laura Espinosa-de-Los-MonterosExperimental Endocrinology Unit/Endocrine Service, Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Sur 132 number 142, Suite 210, Colonia las Americas, Mexico City, 01120, Mexico.
Ernesto SosaExperimental Endocrinology Unit/Endocrine Service, Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Sur 132 number 142, Suite 210, Colonia las Americas, Mexico City, 01120, Mexico.
Baldomero GonzálezExperimental Endocrinology Unit/Endocrine Service, Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Sur 132 number 142, Suite 210, Colonia las Americas, Mexico City, 01120, Mexico.
Sergio ZúñigaExperimental Endocrinology Unit/Endocrine Service, Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Sur 132 number 142, Suite 210, Colonia las Americas, Mexico City, 01120, Mexico.
Martina UnterländerInstitute of Anthropology, Johannes Gutenberg University, Mainz, Germany.
Joachim BurgerInstitute of Anthropology, Johannes Gutenberg University, Mainz, Germany.
Karen StalsDepartment of Molecular Genetics, Royal Devon and Exeter, NHS Foundation Trust, Exeter, UK.
Anne-Marie BussellDepartment of Molecular Genetics, Royal Devon and Exeter, NHS Foundation Trust, Exeter, UK.
Sian EllardDepartment of Molecular Genetics, Royal Devon and Exeter, NHS Foundation Trust, Exeter, UK.
Mary DangCentre for Endocrinology, The William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London, UK.
Donato IacovazzoCentre for Endocrinology, The William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London, UK.
Sonal KapurCentre for Endocrinology, The William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London, UK.
Plamena GabrovskaCentre for Endocrinology, The William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London, UK.
Serban RadianCentre for Endocrinology, The William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London, UK.
Federico RoncaroliDivision of Neuroscience and Experimental Psychology, University of Manchester, Manchester, UK.
Márta KorbonitsCentre for Endocrinology, The William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London, UK.
Moisés MercadoExperimental Endocrinology Unit/Endocrine Service, Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Sur 132 number 142, Suite 210, Colonia las Americas, Mexico City, 01120, Mexico. moises.mercado@endocrinologia.org.mx.
Queen Mary University of London · GBCentro Médico ABC · MXHospital de Especialidades · MXRoyal Devon & Exeter NHS Foundation Trust · GBWilliam Harvey Research Institute · GBJohannes Gutenberg University Mainz · DEMexican Social Security Institute · MXCentro Medico Nacional Siglo XXI · MXInstituto Nacional de Neurología y Neurocirugía · MXUniversity of Manchester · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although aryl hydrocarbon receptor-interacting protein (AIP) mutations are rare in sporadic acromegaly, their prevalence among young patients is nonnegligible. The objectives of this study were to evaluate the frequency of AIP mutations in a cohort of Mexican patients with acromegaly with disease onset before the age of 30 and to search for molecular abnormalities in the AIP gene in teeth obtained from the "Tampico Giant". Peripheral blood DNA from 71 patients with acromegaly (51 females) with disease onset <30 years was analysed (median age of disease onset of 23 years) and correlated with clinical, biochemical and imaging characteristics. Sequencing was also carried out in DNA extracted from teeth of the Tampico Giant. Five patients (7 %) harboured heterozygous, germline mutations of the AIP gene. In two of them (a 9-year-old girl with gigantism and a young man with symptoms of GH excess since age 14) the c.910C>T (p.Arg304Ter), well-known truncating mutation was identified; in one of these two cases and her identical twin sister, the mutation proved to be a de novo event, since neither of their parents were found to be carriers. In the remaining three patients, new mutations were identified: a frameshift mutation (c.976_977insC, p.Gly326AfsTer), an in-frame deletion (c.872_877del, p.Val291_Leu292del) and a nonsense mutation (c.868A > T, p.Lys290Ter), which are predicted to be pathogenic based on in silico analysis. Patients with AIP mutations tended to have an earlier onset of acromegaly and harboured larger and more invasive tumours. A previously described genetic variant of unknown significance (c.869C > T, p.Ala299Val) was identified in DNA from the Tampico Giant. The prevalence of AIP mutations in young Mexican patients with acromegaly is similar to that of European cohorts. Our results support the need for genetic evaluation of patients with early onset acromegaly.

Indexed as

AcromegalyAdenomaAdolescentAdultFemaleGene FrequencyGigantismGrowth Hormone-Secreting Pituitary AdenomaHumansIntracellular Signaling Peptides and ProteinsMaleMexicoMutationYoung Adultaryl hydrocarbon receptor-interacting proteinIntracellular Signaling Peptides and ProteinsAcromegalyAIPFIPAGigantism

Identifiers

PMID27033541
OpenAlexW2314823053

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.